Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2024, with a reporting date of April 15, 2024. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The transactions occurred on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on individual share transactions.
| Transaction Type | Instrument | Price | Volume Range |
|---|---|---|---|
| Share Reward Plan | Ordinary Shares | £16.1277 | 14 to 16 shares |
| Dividend Re-investment | Ordinary Shares | £16.2891 - £16.3860 | 3 to 1,090 shares |
| Dividend Re-investment | American Depositary Shares (ADS) | $40.9550 | 9 to 68 shares |
Material Changes
The filing does not report material changes to the company's financial position or operations. It documents routine compliance disclosures regarding insider shareholdings. The transactions reflect standard participation in the Company's Share Reward Plan and the automatic re-investment of dividends paid on April 11, 2024.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. The document is a statutory notification of share ownership changes and contains no strategic updates or contingency information.
Important Facts for Investors
- Transaction Nature: All reported transactions are acquisitions, consisting of either shares acquired under the Share Reward Plan or shares purchased via dividend re-investment plans.
- Participants: Transactions involve senior executives (including CEO Emma Walmsley and CFO Julie Brown), other PDMRs, and Independent Non-Executive Directors.
- Timing: Share Reward Plan acquisitions occurred on April 10, 2024. Dividend re-investment transactions occurred on April 11 and April 12, 2024.
- Valuation: Ordinary shares were acquired at approximately £16.13 to £16.39, while ADSs were acquired at approximately $40.96.
- Scope: This filing is not a financial results report; investors should refer to Form 20-F or quarterly earnings releases for corporate financial performance.